High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study.

Paul G. Richardson, Kenneth C. Anderson, Andrzej Jakubowiak et al.|Blood|2009

Cited by 8